AU2003201559A1 - Multispecific binding molecules - Google Patents

Multispecific binding molecules

Info

Publication number
AU2003201559A1
AU2003201559A1 AU2003201559A AU2003201559A AU2003201559A1 AU 2003201559 A1 AU2003201559 A1 AU 2003201559A1 AU 2003201559 A AU2003201559 A AU 2003201559A AU 2003201559 A AU2003201559 A AU 2003201559A AU 2003201559 A1 AU2003201559 A1 AU 2003201559A1
Authority
AU
Australia
Prior art keywords
binding molecules
multispecific binding
multispecific
molecules
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003201559A
Other languages
English (en)
Other versions
AU2003201559A8 (en
Inventor
William Herman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2002/000317 external-priority patent/WO2002072141A2/en
Priority claimed from CA 2397169 external-priority patent/CA2397169A1/en
Priority claimed from CA 2402930 external-priority patent/CA2402930A1/en
Application filed by Individual filed Critical Individual
Publication of AU2003201559A8 publication Critical patent/AU2003201559A8/xx
Publication of AU2003201559A1 publication Critical patent/AU2003201559A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
AU2003201559A 2002-01-14 2003-01-14 Multispecific binding molecules Abandoned AU2003201559A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CA2368708 2002-01-14
CA2,368,708 2002-01-14
PCT/CA2002/000317 WO2002072141A2 (en) 2001-03-09 2002-03-11 Targeted ligands
AU2002240751 2002-03-11
CA 2397169 CA2397169A1 (en) 2002-08-13 2002-08-13 Targeted ligands
CA2,397,169 2002-08-13
CA2,402,930 2002-09-19
CA 2402930 CA2402930A1 (en) 2002-09-19 2002-09-19 Targeted ligands
PCT/CA2003/000044 WO2003057732A2 (en) 2002-01-14 2003-01-14 Multispecific binding molecules

Publications (2)

Publication Number Publication Date
AU2003201559A8 AU2003201559A8 (en) 2003-07-24
AU2003201559A1 true AU2003201559A1 (en) 2003-07-24

Family

ID=27426779

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003201559A Abandoned AU2003201559A1 (en) 2002-01-14 2003-01-14 Multispecific binding molecules

Country Status (4)

Country Link
EP (1) EP1497331A2 (de)
AU (1) AU2003201559A1 (de)
CA (1) CA2513287A1 (de)
WO (1) WO2003057732A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5735194B2 (ja) 2005-01-25 2015-06-17 セル セラピューティクス インコーポレーテッド 改善された生体内半減期を有する生物学的に活性なタンパク質
EP3634999A1 (de) * 2017-06-07 2020-04-15 Philogen S.p.A. Gefässendothelwachstumsfaktor-/antifibronectin-antikörper-fusionsproteine
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000360A1 (en) * 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
JPH05504841A (ja) * 1990-09-14 1993-07-22 バイオサイト・ダイアグノスティックス・インコーポレイテッド リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途
DE69719529T2 (de) * 1996-10-17 2003-12-11 Immunomedics, Inc. Nichtantigenes toxinkonjugat und fusionsprotein eines internalisierendes rezeptorsystems
EP1045861B1 (de) * 1998-01-15 2009-03-04 Center For Molecular Medicine And Immunology Bispezifische "targeting moiety" umfassend einen antikörper gegen cea (carcinoembryonic antigen) und die liganden-bindende region der il13rezeptor alpha untereinheit
WO2000018806A1 (de) * 1998-09-25 2000-04-06 Horst Lindhofer Bispezifische und trispezifische antikörper, die spezifisch mit induzierbaren oberflächenantigenen als operationelle zielstrukturen reagieren
ES2659376T3 (es) * 2000-06-05 2018-03-15 Altor Bioscience Corporation Proteínas de fusión del receptor de linfocitos T y conjugados y procedimientos de uso de las mismas
US20050118164A1 (en) * 2001-03-09 2005-06-02 William Herman Targeted ligands

Also Published As

Publication number Publication date
AU2003201559A8 (en) 2003-07-24
WO2003057732A2 (en) 2003-07-17
EP1497331A2 (de) 2005-01-19
CA2513287A1 (en) 2003-07-17
WO2003057732A3 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
AU2003288304A1 (en) Novel molecules derived from noraporphine
AU2003303586A1 (en) Methods for attaching molecules
EP1585970A3 (de) Verfahren zur trennung von molek len
AU2003272930A1 (en) Footwere
IL166361A0 (en) Binding molecules
EP1572168A3 (de) Anti-infarkt-moleküle
AU2002951388A0 (en) Bookmark
AU2003904230A0 (en) Snowboard binding
AU2003274573A1 (en) Deburrer
AU2003201559A1 (en) Multispecific binding molecules
AU2003236612A1 (en) Secretory molecules
AU2003212825A1 (en) Aggrecanase molecules
AU2003904181A0 (en) Clamp
AU2003243143A1 (en) 2-methyl-thieno-benzodiazepine process
AU2003275529A1 (en) Binding strap rack
AU2003230760A1 (en) Lipid-associated molecules
AU2003276655A1 (en) Pi - conjugated molecules
AU2003903723A0 (en) Process
AU2003241210A1 (en) Videocomputer
GB0219013D0 (en) Modified integration binding molecules
GB0327532D0 (en) Specific binding molecules
AU2003901533A0 (en) Bookmark
AU2003906979A0 (en) Novel binding domain
AU2003900307A0 (en) Novel binding domain
AU2003904694A0 (en) Purifying molecules

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase